The Unyvero platform detects of a broad panel of bacteria and antibiotic resistances from a single sample in one run.
It processes a disposable cartridge providing the necessary reagents to complete the analysis from sample to result.
The platform enables the DNA-based testing of all clinically relevant samples in a fully automated, unsupervised analysis process requiring only few, quick manual preparation steps.
The additional funds will allow Curetis to pursue a more aggressive strategy towards initiating a US clinical trial in H2-2011 with a goal of filing for FDA approval in 2012.
CD-Venture joined the funding as a new investor, while all of Curetis’ existing VC investors participated in the round.
Curetis CEO Schacht said from this solid financial position they will also evaluate further opportunities to accelerate commercialization and broaden pipeline.
"In doing so we are also considering adding another investor and raising additional capital as we continue executing on our plans," Schacht said.
